Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

George Ntaios; Menno V. Huisman; Hans Christoph Diener; Jonathan L. Halperin; Christine Teutsch; Sabrina Marler; Venkatesh K. Gurusamy; Milla Thompson; Gregory Y.H. Lip; Brian Olshansky; Dzifa Wosornu Abban; Nasser Abdul; Atilio Marcelo Abud; Fran Adams; Srinivas Addala; Pedro Adragão; Walter Ageno; Rajesh Aggarwal; Sergio Agosti; Piergiuseppe Agostoni; Francisco Aguilar; Julio Aguilar Linares; Luis Aguinaga; Jameel Ahmed; Allessandro Aiello; Paul Ainsworth; Jorge Roberto Aiub; Raed Al-Dallow; Lisa Alderson; Jorge Antonio Aldrete Velasco; Dimitrios Alexopoulos; Fernando Alfonso Manterola; Pareed Aliyar; David Alonso; Fernando Augusto Alves da Costa; José Amado; Walid Amara; Mathieu Amelot; Nima Amjadi; Fabrizio Ammirati; Marianna Andrade; Nabil Andrawis; Giorgio Annoni; Gerardo Ansalone; M. Kevin Ariani; Juan Carlos Arias; Sébastien Armero; Chander Arora; Gershan Davis; David Williams; the GLORIA-AF Investigators

doi:10.1016/j.hjc.2020.11.009

Anticoagulant selection in relation to the SAMe-TT₂R₂ score in patients with atrial fibrillation: The GLORIA-AF registry

George Ntaios^*, Menno V. Huisman, Hans Christoph Diener, Jonathan L. Halperin, Christine Teutsch, Sabrina Marler, Venkatesh K. Gurusamy, Milla Thompson, Gregory Y.H. Lip, Brian Olshansky, Dzifa Wosornu Abban, Nasser Abdul, Atilio Marcelo Abud, Fran Adams, Srinivas Addala, Pedro Adragão, Walter Ageno, Rajesh Aggarwal, Sergio Agosti, Piergiuseppe AgostoniFrancisco Aguilar, Julio Aguilar Linares, Luis Aguinaga, Jameel Ahmed, Allessandro Aiello, Paul Ainsworth, Jorge Roberto Aiub, Raed Al-Dallow, Lisa Alderson, Jorge Antonio Aldrete Velasco, Dimitrios Alexopoulos, Fernando Alfonso Manterola, Pareed Aliyar, David Alonso, Fernando Augusto Alves da Costa, José Amado, Walid Amara, Mathieu Amelot, Nima Amjadi, Fabrizio Ammirati, Marianna Andrade, Nabil Andrawis, Giorgio Annoni, Gerardo Ansalone, M. Kevin Ariani, Juan Carlos Arias, Sébastien Armero, Chander Arora, Gershan Davis, David Williams, the GLORIA-AF Investigators

^*Corresponding author for this work

Research output: Contribution to journal › Article (journal) › peer-review

3 Citations (Scopus)

31 Downloads (Pure)

Abstract

Aim: The SAMe-TT₂R₂ score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT₂R₂ scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT₂R₂ score >2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT₂R₂ scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT₂R₂ scores >2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT₂R₂ score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT₂R₂-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007.

Original language	English
Pages (from-to)	152-157
Number of pages	6
Journal	Hellenic Journal of Cardiology
Volume	62
Issue number	2
Early online date	15 Dec 2020
DOIs	https://doi.org/10.1016/j.hjc.2020.11.009
Publication status	Published - 11 Jun 2021

Keywords

atrial fibrillation
non-vitamin-K antagonist oral anticoagulants
SAMe-TTR
vitamin-K-antagonist oral anticoagulants

Access to Document

10.1016/j.hjc.2020.11.009Licence: CC BY-NC-ND

1-s2.0-S1109966620302815-mainFinal published version, 491 KBLicence: CC BY-NC-ND

Cite this

Ntaios, G., Huisman, M. V., Diener, H. C., Halperin, J. L., Teutsch, C., Marler, S., Gurusamy, V. K., Thompson, M., Lip, G. Y. H., Olshansky, B., Abban, D. W., Abdul, N., Abud, A. M., Adams, F., Addala, S., Adragão, P., Ageno, W., Aggarwal, R., Agosti, S., ... the GLORIA-AF Investigators (2021). Anticoagulant selection in relation to the SAMe-TT₂R₂ score in patients with atrial fibrillation: The GLORIA-AF registry. Hellenic Journal of Cardiology, 62(2), 152-157. https://doi.org/10.1016/j.hjc.2020.11.009

@article{2e57a43a194548d5abab25b23a49cbc7,

title = "Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry",

abstract = "Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007.",

keywords = "atrial fibrillation, non-vitamin-K antagonist oral anticoagulants, SAMe-TTR, vitamin-K-antagonist oral anticoagulants",

author = "George Ntaios and Huisman, {Menno V.} and Diener, {Hans Christoph} and Halperin, {Jonathan L.} and Christine Teutsch and Sabrina Marler and Gurusamy, {Venkatesh K.} and Milla Thompson and Lip, {Gregory Y.H.} and Brian Olshansky and Abban, {Dzifa Wosornu} and Nasser Abdul and Abud, {Atilio Marcelo} and Fran Adams and Srinivas Addala and Pedro Adrag{\~a}o and Walter Ageno and Rajesh Aggarwal and Sergio Agosti and Piergiuseppe Agostoni and Francisco Aguilar and Linares, {Julio Aguilar} and Luis Aguinaga and Jameel Ahmed and Allessandro Aiello and Paul Ainsworth and Aiub, {Jorge Roberto} and Raed Al-Dallow and Lisa Alderson and {Aldrete Velasco}, {Jorge Antonio} and Dimitrios Alexopoulos and Manterola, {Fernando Alfonso} and Pareed Aliyar and David Alonso and {Alves da Costa}, {Fernando Augusto} and Jos{\'e} Amado and Walid Amara and Mathieu Amelot and Nima Amjadi and Fabrizio Ammirati and Marianna Andrade and Nabil Andrawis and Giorgio Annoni and Gerardo Ansalone and Ariani, {M. Kevin} and Arias, {Juan Carlos} and S{\'e}bastien Armero and Chander Arora and Gershan Davis and David Williams and {the GLORIA-AF Investigators}",

note = "Publisher Copyright: {\textcopyright} 2020 Hellenic Society of Cardiology",

year = "2021",

month = jun,

day = "11",

doi = "10.1016/j.hjc.2020.11.009",

language = "English",

volume = "62",

pages = "152--157",

journal = "Hellenic Journal of Cardiology",

issn = "1109-9666",

publisher = "Hellenic Cardiological Society",

number = "2",

}

Ntaios, G, Huisman, MV, Diener, HC, Halperin, JL, Teutsch, C, Marler, S, Gurusamy, VK, Thompson, M, Lip, GYH, Olshansky, B, Abban, DW, Abdul, N, Abud, AM, Adams, F, Addala, S, Adragão, P, Ageno, W, Aggarwal, R, Agosti, S, Agostoni, P, Aguilar, F, Linares, JA, Aguinaga, L, Ahmed, J, Aiello, A, Ainsworth, P, Aiub, JR, Al-Dallow, R, Alderson, L, Aldrete Velasco, JA, Alexopoulos, D, Manterola, FA, Aliyar, P, Alonso, D, Alves da Costa, FA, Amado, J, Amara, W, Amelot, M, Amjadi, N, Ammirati, F, Andrade, M, Andrawis, N, Annoni, G, Ansalone, G, Ariani, MK, Arias, JC, Armero, S, Arora, C, Davis, G , Williams, D & the GLORIA-AF Investigators 2021, 'Anticoagulant selection in relation to the SAMe-TT₂R₂ score in patients with atrial fibrillation: The GLORIA-AF registry', Hellenic Journal of Cardiology, vol. 62, no. 2, pp. 152-157. https://doi.org/10.1016/j.hjc.2020.11.009

TY - JOUR

T1 - Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation

T2 - The GLORIA-AF registry

AU - Ntaios, George

AU - Huisman, Menno V.

AU - Diener, Hans Christoph

AU - Halperin, Jonathan L.

AU - Teutsch, Christine

AU - Marler, Sabrina

AU - Gurusamy, Venkatesh K.

AU - Thompson, Milla

AU - Lip, Gregory Y.H.

AU - Olshansky, Brian

AU - Abban, Dzifa Wosornu

AU - Abdul, Nasser

AU - Abud, Atilio Marcelo

AU - Adams, Fran

AU - Addala, Srinivas

AU - Adragão, Pedro

AU - Ageno, Walter

AU - Aggarwal, Rajesh

AU - Agosti, Sergio

AU - Agostoni, Piergiuseppe

AU - Aguilar, Francisco

AU - Linares, Julio Aguilar

AU - Aguinaga, Luis

AU - Ahmed, Jameel

AU - Aiello, Allessandro

AU - Ainsworth, Paul

AU - Aiub, Jorge Roberto

AU - Al-Dallow, Raed

AU - Alderson, Lisa

AU - Aldrete Velasco, Jorge Antonio

AU - Alexopoulos, Dimitrios

AU - Manterola, Fernando Alfonso

AU - Aliyar, Pareed

AU - Alonso, David

AU - Alves da Costa, Fernando Augusto

AU - Amado, José

AU - Amara, Walid

AU - Amelot, Mathieu

AU - Amjadi, Nima

AU - Ammirati, Fabrizio

AU - Andrade, Marianna

AU - Andrawis, Nabil

AU - Annoni, Giorgio

AU - Ansalone, Gerardo

AU - Ariani, M. Kevin

AU - Arias, Juan Carlos

AU - Armero, Sébastien

AU - Arora, Chander

AU - Davis, Gershan

AU - Williams, David

AU - the GLORIA-AF Investigators

PY - 2021/6/11

Y1 - 2021/6/11

N2 - Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007.

AB - Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007.

KW - atrial fibrillation

KW - non-vitamin-K antagonist oral anticoagulants

KW - SAMe-TTR

KW - vitamin-K-antagonist oral anticoagulants

UR - http://www.scopus.com/inward/record.url?scp=85100117647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100117647&partnerID=8YFLogxK

U2 - 10.1016/j.hjc.2020.11.009

DO - 10.1016/j.hjc.2020.11.009

M3 - Article (journal)

C2 - 33338644

AN - SCOPUS:85100117647

SN - 1109-9666

VL - 62

SP - 152

EP - 157

JO - Hellenic Journal of Cardiology

JF - Hellenic Journal of Cardiology

IS - 2

ER -

Anticoagulant selection in relation to the SAMe-TT₂R₂ score in patients with atrial fibrillation: The GLORIA-AF registry

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this